Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

10/02/2026 Eastern Time in USA The Dow Jones Industrial Average rose by 0.1%, closing at 50188.14 points; the Nasdaq Composite dropped by 0.59%, closing at 23102.47 points; the S&P 500 Index dropped by 0.33%, closing at 6941.81 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

Evommune, Inc.: Overnight gain 70.9%, Core product shows promising clinical trial results, boosting investor confidence in company's research capabilities.

Evommune, Inc., a clinical-stage biotechnology firm, was established in April 2020 and is incorporated in Delaware with its headquarters in Palo Alto, California. The company is dedicated to developing innovative therapies targeting key pathogenic drivers of chronic inflammatory diseases. The firm's initial clinical development pipeline focuses on addressing unmet medical needs in areas such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Evommune's strategic approach aims to leverage cutting-edge science to create novel treatment options for patients suffering from these challenging conditions. As a relatively young player in the biotech sector, Evommune is positioning itself at the forefront of inflammation research, with the potential to disrupt traditional treatment paradigms in its target therapeutic areas. The company's progress will be closely watched by industry observers and potential investors as it advances its pipeline through clinical trials.

Evommune, Inc. (EVMN) shares surged 70.9% following positive results from the Phase 2a clinical trial of its flagship product, EVO301, for moderate to severe atopic dermatitis. The study met its primary efficacy endpoint at week 12, with EVO301 demonstrating a significant 33% improvement in EASI scores compared to placebo. Additionally, 23% of patients achieved an IGA score of 0/1. The rigorous randomized, double-blind, placebo-controlled trial design lends credibility to the results, bolstering confidence in Evommune's research capabilities and EVO301's market potential. This promising outcome for the treatment of atopic dermatitis has sparked investor optimism, driving the substantial stock price increase. The successful trial results underscore Evommune's position in the competitive dermatology therapeutics market and suggest potential for future growth.

Nektar Therapeutics: Overnight gain 51.1%, Clinical trial progress boosts investor confidence in atopic dermatitis treatment

Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical firm established in 1990, is at the forefront of innovative drug development in the burgeoning field of immunotherapy. The company's primary focus lies in the creation of novel immunomodulators, designed to selectively regulate immune responses for targeted therapeutic outcomes. As a clinical-stage research enterprise, Nektar Therapeutics continues to push the boundaries in this rapidly evolving sector. The firm's pipeline is dedicated to advancing potential breakthrough treatments, aiming to address unmet medical needs and enhance patient outcomes in various therapeutic areas. With its commitment to cutting-edge research and development, Nektar Therapeutics is positioning itself as a key player in the competitive landscape of immune-oncology and immunotherapy. The company's strategic approach to drug discovery and development underscores its mission to deliver more efficacious treatment options to patients, potentially reshaping the future of immune-mediated therapies. Investors and industry observers are closely monitoring Nektar Therapeutics' progress, as its innovative pipeline could potentially yield significant advancements in the treatment of immune-related disorders and oncology.

Nektar Therapeutics (NKTR) shares surged on significant clinical trial progress. The company announced the completion of target patient enrollment for its REZOLVE-AD Phase 2b trial, evaluating rezpegaldesleukin for moderate to severe atopic dermatitis. Positive 36-week blinded maintenance treatment data further bolstered market confidence. Nektar plans to reveal topline results from the 36-week maintenance period of the REZOLVE-AD Phase 2b trial on February 10, 2026, sparking investor anticipation of potential positive outcomes. These developments collectively propelled Nektar Therapeutics' stock to a remarkable 51.1% gain on the day, bringing its year-to-date increase to 32.5%. The company's progress in clinical trials has significantly improved investor sentiment and market outlook for Nektar Therapeutics.

European Wax Center, Inc. Class A: Overnight gain 43.0%, Stock surges on strong business model, innovation, and expansion strategy in beauty industry.

European Wax Center, Inc. (NASDAQ: EWCZ), a Delaware-incorporated entity established in 2021, has positioned itself as a premier provider in the personal care services sector. The company's business model centers on delivering superior customer experiences, distinguishing itself from smaller chain establishments and independent salons in the beauty industry. EWCZ's core offering comprises high-quality, hygienic hair removal services, administered by a team of trained and licensed estheticians at strategically located centers. The company has implemented a tech-driven customer interface, featuring automated booking systems and remote check-in capabilities, which streamlines the client experience and ensures accessibility, consistency, and convenience. The firm's operational philosophy is deeply rooted in customer-centricity, with a strong focus on maintaining a competitive edge in the hair removal service market. This strategic approach aligns with the company's commitment to excellence and its aim to capture a significant market share in the personal care industry. As European Wax Center, Inc. continues to expand its footprint, investors and industry analysts will be closely monitoring its performance metrics and growth strategies in the highly competitive beauty and personal care sector.

European Wax Center, Inc. Class A (EWCZ) experienced a remarkable surge in its stock price, climbing 43.0% in overnight trading and achieving a year-to-date gain of 58.9%. This significant growth can be attributed to the company's robust business model, efficiency improvements driven by technological innovations, and successful implementation of expansion strategies. As a specialized service provider in the beauty care industry, EWCZ has benefited from the sector's overall growth trends. Furthermore, the company's release of financial results that exceeded market expectations or optimistic future outlook has likely sparked investor recognition of its growth potential, fueling the stock's upward momentum. This impressive performance underscores EWCZ's strong position in the competitive beauty care market and its ability to capitalize on industry tailwinds.

KAWASAKI HEAVY INDUSTRIES: Overnight gain 36.8%, Global manufacturing recovery and infrastructure investments boost investor optimism, driving stock price upward.

Company profile missing.

The recent surge in KAWASAKI HEAVY INDUSTRIES(KWHIF) stock price can be attributed to multiple factors. As a prominent Japanese heavy industry conglomerate, the significant uptick in KWHIF's share value reflects investors' optimistic outlook on global manufacturing recovery. The company's core businesses, spanning aerospace, shipbuilding, and machinery equipment sectors, are poised to benefit from the global economic rebound and increased infrastructure investments. Additionally, fluctuations in the yen exchange rate and potential new order acquisitions may have contributed to the stock's upward trajectory. However, for a comprehensive understanding of the price movement, it is essential to closely monitor company announcements and industry trends. The multifaceted nature of KAWASAKI HEAVY INDUSTRIES(KWHIF)'s operations underscores its potential to capitalize on various economic tailwinds.

Haverty Furniture Companies, Inc. Class A: Overnight gain 35.8%, Furniture retailer benefits from housing recovery, wide market coverage, and strong brand reputation.

Haverty Furniture Companies, Inc. (NYSE: HVT) is a leading mid to upper-end residential furniture retailer, operating 121 Havertys-branded showrooms across 16 states without franchised locations. The company offers proprietary credit programs and third-party financing options, focusing exclusively on home furnishings retail operations. Founded in 1885 by J.J. Haverty in Atlanta, the business evolved from a single-store operation with horse-drawn delivery to a network of 18 stores by the time of its initial public offering in 1929. This milestone provided the company with additional capital to fuel further expansion. With a rich history spanning over 135 years, Haverty Furniture Companies has established itself as a prominent player in the home furnishings industry, catering to discerning customers seeking quality furniture and home accessories. The company's strategic focus on its core retail business and commitment to customer service have been key factors in its long-term success and market position.

The recent surge in Haverty Furniture Companies, Inc. Class A (HVT.A) stock price can be attributed to multiple factors. As a mid-to-high-end residential furniture retailer, HVT.A has benefited from the recovery in the real estate market and home furnishing consumption. The company's extensive network of 121 showrooms across 16 states has facilitated growth in diverse regional markets. Additionally, Haverty's long-standing brand history and financing services have bolstered its competitive edge. The impressive overnight gain of 35.8% and year-to-date increase of 64.9% reflect investors' optimistic outlook on the company's prospects, further fueling the stock's upward momentum. This positive sentiment underscores the market's confidence in Haverty Furniture Companies, Inc. Class A (HVT.A) and its potential for continued growth in the furniture retail sector.

Energy Services of America Corporation: Overnight gain 33.5%, Strong financial performance and improved profitability boost investor confidence in growth prospects.

Energy Services of America Corporation (ESOA), established in 2006, is a diversified contracting and service company operating primarily in the Mid-Atlantic and Midwest regions of the United States. The firm specializes in providing comprehensive services to a range of industries, including natural gas, petroleum, water distribution, automotive, chemical, and power sectors. ESOA's core competencies lie in the construction, replacement, and maintenance of natural gas pipelines and storage facilities. The company's service portfolio extends to electrical and mechanical installation and maintenance, pipeline-related solutions, corrosion protection, and horizontal directional drilling. In recent years, ESOA has strategically expanded its operations to capitalize on emerging market opportunities. The company has diversified into new business segments, including broadband installation, solar energy systems, and residential general contracting. This expansion aligns with the company's commitment to meeting evolving market demands and enhancing its service offerings. By broadening its scope of services, ESOA aims to strengthen its market position and create additional revenue streams, potentially driving long-term growth and shareholder value.

Energy Services of America Corporation (ESOA) has experienced a significant stock price surge, driven by its impressive financial performance in the first quarter of fiscal 2026. The company's net income soared by over 300% year-over-year to $2.71 million, while total revenue climbed 13.4% to $114.1 million. ESOA's profitability improved, with gross margin expanding by 2.1 percentage points to 12.3%. Earnings per share reached $0.16, surpassing analyst expectations by 77.78%. The natural gas and water distribution segments demonstrated robust growth, with revenue increasing by 30%. A $41.7 million quarter-over-quarter increase in backlog orders provides a solid foundation for future growth. These factors collectively propelled ESOA's stock price to a single-day gain of 33.5%, bringing its year-to-date increase to 55.2%, reflecting market optimism about the company's prospects.

Ichor Holdings, Ltd.: Overnight gain 32.7%, Strong Q4 results, positive Q1 guidance, and strategic transformation boost investor confidence.

Ichor Holdings, Ltd. is a leading manufacturer of critical fluid delivery subsystems for semiconductor capital equipment. The company's primary product offerings include gas and chemical delivery subsystems, which are integral to the tool sets used in the manufacturing of semiconductor devices. Ichor's gas delivery subsystems are designed to precisely control the volume and pressure of gases used in various processes such as etching and deposition. Meanwhile, their chemical delivery subsystems are engineered to accurately blend and dispense liquid chemicals crucial for processes including chemical mechanical planarization (CMP), electroplating, and cleaning. In addition to these core offerings, Ichor produces components used within their systems and also sells them directly to customers. The company's business model is characterized by vertical integration, with a particular focus on the production of metal and plastic components required for gas and chemical systems. This strategic positioning allows Ichor to maintain a competitive edge in the semiconductor equipment supply chain, providing critical solutions that enable the advancement of semiconductor manufacturing technologies.

Ichor Holdings, Ltd. (ICHR) experienced a notable surge in stock price due to multiple factors. The company's Q4 financial results surpassed market expectations, reporting earnings per share of $0.01, outperforming analysts' projected loss of $0.06. Additionally, ICHR's Q1 guidance exceeded market estimates, forecasting adjusted EPS of $0.08-$0.16 and revenue of $240-$260 million, both surpassing analyst predictions. The firm is undergoing a strategic transformation, aiming to increase Ichor-branded products to 75% of supply system content by 2026, potentially boosting profit margins. ICHR is also diversifying into non-semiconductor sectors to mitigate risks. Management expressed strong confidence in the company's outlook through fiscal 2026, projecting growth every quarter. Several analysts have upgraded Ichor Holdings' ratings and price targets, further fueling the stock's upward momentum.

Neumora Therapeutics, Inc.: Overnight gain 25.1%, Innovative neuroscience portfolio and promising depression treatment drive stock surge amid sector optimism.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical firm founded in 2019, is at the forefront of developing innovative therapies for brain disorders. The company's robust pipeline comprises seven clinical and preclinical neuroscience programs, targeting a wide spectrum of neuropsychiatric and neurodegenerative conditions. The company's lead candidate, navacaprant, is an oral kappa opioid receptor antagonist currently in development for the treatment of major depressive disorder (MDD). This novel compound shows promise in potentially offering significant advantages to patients suffering from this debilitating condition. Neumora's strategic focus lies in addressing the global brain health crisis through its unique approach to neuroscience. By leveraging cutting-edge research and innovative methodologies, the company aims to revolutionize the treatment landscape for neurological disorders. As Neumora Therapeutics continues to advance its pipeline and expand its therapeutic reach, it positions itself as a key player in the rapidly evolving neuroscience sector, potentially unlocking new possibilities for patients worldwide.

Neumora Therapeutics, Inc. (NMRA) has experienced a notable surge in stock price, driven by multiple factors. The company's focus on developing innovative treatments for brain disorders, with seven clinical and preclinical neuroscience programs, has garnered significant investor attention. Their lead product, navacaprant, currently in development for major depressive disorder, shows promising market potential. The rising interest in neuroscience, coupled with a generally positive outlook for the biopharmaceutical sector, has contributed to NMRA's substantial stock appreciation. Additionally, the company's diversified product portfolio has enhanced its investment appeal by potentially mitigating risk. This combination of factors has positioned Neumora Therapeutics as an attractive prospect in the competitive biotech landscape, fueling investor optimism and driving the stock's upward trajectory.

Lumexa Imaging Holdings, Inc.: Overnight gain 21.3%, Analyst upgrade and industry leadership boost stock amid valuation recovery expectations.

Lumexa Imaging Holdings, Inc., a Delaware-incorporated entity established on November 14, 2025, has emerged as a leading provider of diagnostic imaging services in the United States. The company operates an integrated, scalable platform designed to generate value for stakeholders through superior performance. Strategically positioned in convenient retail settings, Lumexa's imaging centers offer flexible appointment schedules to accommodate patient needs. The firm has successfully developed a diversified network of referring physicians, ensuring broad market coverage. Lumexa places a strong emphasis on delivering high-quality care, equipping its facilities with state-of-the-art technology and staffing them with skilled professionals. This commitment to excellence underpins the company's service offerings and market position. As a key player in the diagnostic imaging sector, Lumexa Imaging Holdings, Inc. continues to leverage its innovative business model and focus on quality to drive growth and maintain its competitive edge in the evolving healthcare landscape.

Lumexa Imaging Holdings, Inc. (LMRI) experienced a significant stock price surge due to multiple factors. Notably, Raymond James analysts upgraded LMRI from "outperform" to "strong buy" with a price target of $23, signaling confidence in the company's outlook. As one of the largest diagnostic imaging service providers in the United States, LMRI's industry position and fundamental strengths have gained recognition. Despite a 24.3% year-to-date decline, the stock's 21.3% daily gain reflects investors' expectations for valuation recovery. These factors collectively contributed to LMRI's substantial stock price appreciation. The market's positive response underscores the potential for LMRI to capitalize on its strategic advantages and industry leadership in the diagnostic imaging sector.

LuxExperience BV: Overnight gain 21.1%, Luxury market recovery and strong digital presence boost investor confidence in multi-brand platform.

LuxExperience B.V., a global leader in the luxury multi-brand digital platform space, serves customers in over 130 countries. The company curates a selection of more than 200 premium brands, offering a comprehensive range of apparel and lifestyle products. The firm's roots can be traced back over three decades to the Theresa boutique in Munich. In 2006, the company launched its digital platform, Mytheresa, marking a significant milestone in its evolution. LuxExperience B.V. has distinguished itself in the market by combining exclusive product offerings, differentiated customer service, and cutting-edge technology to create a unique digital experience for luxury consumers. Leveraging deep market insights and long-standing relationships with top-tier brands, LuxExperience has established itself as a global frontrunner in the digital luxury sector. On May 2, 2025, the company rebranded to LuxExperience B.V., reflecting its expanded global presence and strategic vision for the future. This strategic positioning and continuous innovation have enabled LuxExperience B.V. to capitalize on the growing trend of luxury e-commerce, solidifying its status as a key player in the digital transformation of the luxury goods industry.

LuxExperience BV (LUXE) experienced a significant stock price surge, driven by multiple factors. As a leading multi-brand digital platform for luxury goods, LUXE has benefited from the global luxury market recovery. The company's robust Mytheresa digital platform, operating in over 130 countries, showcases its e-commerce prowess. LUXE's unique business model, combining digital and physical experiences, along with long-standing partnerships with top brands like Gucci and Prada, has bolstered investor confidence. The recent rebranding is also viewed as a positive signal. The overnight gain of 21.1% and year-to-date increase of 12.1% indicate market optimism towards LUXE, propelling its market capitalization to $1.285 billion. These developments underscore the company's strong position in the luxury retail sector and its potential for continued growth.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team. Risk and Disclaimer: The content provided above is solely for informational purposes and does not represent the views or positions of Sahm Platform. While we strive for accuracy, we cannot guarantee the authenticity or completeness of the information contained in the provided content. We strongly recommend that investors consult with a qualified investment advisor when deemed necessary. Sahm Platform neither provides investment advice nor makes any representations or warranties concerning the accuracy, reliability, or completeness of the information in the content provided above. By using Sahm Platform, you acknowledge that you have read, understood, and agreed to the terms set forth in this disclaimer.